Saturday, July 23, 2016

JBC Forum "NGS(次世代シークエンス)& 遺伝子治療" 初心者でもわかる遺伝子技術&ビジネス最前線

日時:8月13日土曜日 12:30PM-5:00PM
場所:Redwood City Downtown Library, meeting room
Address:1044 Middlefield Road, Redwood City, CA 94063

会場はCaltrainのRedwood Cityステーションから徒歩5分です。




★ 座席に限りアリ。一定数に達した時点で申し込み締め切りと致します。
★ スポンサー企業歓迎。ご支援いただける企業の方ございましたら、登録フォームのNote欄からご一報ください。

12:30- 1:00PM 受付、ネットワーキング

進行役:上原 輝彦、鈴木 智之

1:00PM- 1:30PM Talk1
上原 輝彦, JBC企画委員

1:30PM- 2:00PM Talk 2
"The current status of NGS technologies, industries and future applications"
Tao Chen, CEO, Paragon Genomics, Inc.

2:00PM- 2:15PM 休憩

2:15PM- 2:45PM Talk3
本蔵 俊彦, CEO, QuantumBio, Inc.

2:45PM- 3:15PM Talk4
"NGS application for the cancer research"
Asia Chang, Senior Director, Product Management, Oncology, Thermo Fisher Scientific

3:15PM- 3:45PM Talk 5
Andrew Hilmer, Account Manager, Strategic Business Development, Applied StemCell, Inc.

3:45PM- 4:45PM ネットワーキング

JBCフォーラム企画:水野 和恵、清田 智子、上原 輝彦、鈴木 智之、橋本 千香


Akihiko Uehara(上原 輝彦)

Talk Title: DNA/遺伝子の基礎

Talk Summary: 本日のテーマであるNGS(次世代シーケンス)は遺伝子を解析する技術、遺伝子治療は遺伝子を操作する技術と密接に関連しています。本講演では、バイオのバックグラウンドを持たない方々もNGS・遺伝子治療の専門家の方々の講演を理解できるよう、遺伝子を構成する物質であるDNAとはそもそも何なのか、遺伝子とは何か、遺伝子はどのように解析されるか、遺伝子操作はどのように行われるかについて解説します。

Biography Akihiko (Aki) Uehara has recently joined DEFTA Partners, a life science/ healthcare VC firm, following a successful tenure as a regional Product Manager at Bio-Rad Laboratories in Japan where he launched and grew sales of genomics products including PCR, qPCR, and digital PCR. Prior to Bio-Rad, Aki was a consultant for Deloitte Tohmatsu Consulting where his responsibilities included advising high tech companies on market strategy planning in emerging markets such as India and Vietnam. Aki received his Masters of Engineering in Chemistry and Biotechnology from University of Tokyo and his Masters of Business Administration from the Haas School of Business, UC Berkeley.

Tao Chen

Talk Title: The current status of NGS technologies, industries and future applications

Talk Summary: Next generation sequencing (NGS) has gained popularity and is now widely used for genome-wide sequencing due to its powerful data generation capability combined with cost attractiveness. NGS has shown promising potential for clinical applications, however it still faces many challenges. Mr. Chen will talk about potential applications for NGS and the challenges it faces given the current state of development of the technology. Tao Chen currently leads Paragon Genomics, which is engaged in developing and commercializing rapid, easy-to-use, ultra-high multiplex PCR-based target enrichment solutions for the NGS and precision medicine markets.

Tao Chen is CEO and Founder of Paragon Genomics. Paragon's proprietary CleanPlex™ multiplex PCR technology and custom panel design capability enable NGS customers to develop targeted sequencing assays that can be 5-10 times faster and more accurate than assays based on existing methods. Formerly Senior Product Manager of Thermo Fisher Scientific, and Business Development Manager, Life Technologies. MBA from Harvard University,  BSc from Peking University.

Toshihiko Honkura(本蔵 俊彦), MBA

Talk Title: Nanoporeシーケンサー技術とビジネス展開

Talk Summary: NGS技術は近年目覚ましい進展を遂げており、次世代の技術としてナノポアシーケンサーが注目されています。本講演では、大阪大学発ベンチャーQuantum Biosystems CEOの本蔵様に、ナノポアシーケンシング技術の内容、既存NGS技術に対する利点、技術的課題および解決策、そして日本発の技術を世界のNGS市場に広げるための今後のビジネス展開についてお話しいただきます。

Biography A co-founder of Quantum Biosystems Inc., Toshihiko represents the company as both president and CEO. After a genome research project at the University of Tokyo, he went on to gain ten years’ hands-on experience in business management and investment analysis as a manager at McKinsey & Company and the Innovation Network Corporation of Japan (INCJ), a public-private Japanese fund. He has a master’s degree in Analytical Biochemistry from the University of Tokyo and an MBA from Columbia University. The scientific and business management acumen he brings to the team affords the company excellent and tested leadership.

Asia Chang

Talk Title: Pioneering the Path to Precision Genomics

Talk Summary: Nowhere has the promise of precision medicine been more hopeful, than in our effort to understand and ultimately treat cancer. At a fundamental level, we have learned that cancer is a disease of the genome. NGS technology has enabled researchers to make massive strides in developing this understanding. In the last 3-5 years alone, a plethora of new NGS applications have emerged to shed light on cancer through liquid biopsies and immunology. To harness these findings into meaningful solutions for clinical cancer researchers, Asia Chang will share how Thermo Fisher Scientific is supporting the community with robust NGS oncology solutions.

Biography Asia Chang leads the oncology product management team in the Clinical Next-Generation Sequencing Division (CSD) at Thermo Fisher Scientific. The Oncology team develops clinical research solutions for cancer leveraging the Ion AmpliSeq™ Technology and Ion Torrent™ Sequencing platforms. He originally joined Thermo Fisher leading strategic development and business development activities within the division. Prior to joining Thermo Fisher Scientific, Asia was responsible for strategic engagements at L.E.K. Consulting’s life science practice in the U.S. and China markets serving global pharma, diagnostics, and medical device organizations. Asia began his career in R&D and Product Development at Johnson & Johnson designing minimally invasive medical devices.

Andrew Hilmer, PhD

Talk Title: Emerging Gene-Editing Technologies for Pre-Clinical Discovery and Gene Therapy

Talk Summary: Just over three years ago, the first groundbreaking reports were published that described the ability to utilize the CRISPR/Cas9 system for gene editing in mammalian cells.  Since then, the field has advanced at an incredible pace, with the first clinical trials being approved by a biosafety and ethics panel in June for the utilization of CRISPR-based gene editing in treating human subjects.  Despite these advances, CRISPR technology faces several technical hurdles, which will need to be overcome in order to facilitate widespread application of the technology in the treatment of genetic disorders.  Dr. Hilmer will give an introduction to two gene editing technologies, CRISPR and TARGATT™, and discuss opportunities and challenges in the application of these technologies to preclinical discovery and gene therapy.

BiographyAndrew Hilmer works in Strategic Business Development at Applied StemCell, a leading stem cell and gene-editing company that focuses on the development of products and therapeutics that are enabled by its proprietary gene editing platforms, TARGATT™ and CRISPR/Cas9.  Prior to joining Applied StemCell, Andrew was an NIH Postdoctoral Fellow at Stanford University, and he completing his Ph.D. training in Chemical Engineering at MIT.